FDA Approves Recarbrio (imipenem, cilastatin, and relebactam) for the Treatment of Complicated Urinary Tract and Complicated Intra-Abdominal Bacterial Infections

KENILWORTH, N.J.--(BUSINESS WIRE)-- July 17, 2019 Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Recarbrio (imipenem, cilastatin, and relebactam) for...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news